samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > the emergence of biogenerics
PUBLICATIONS
European Biopharmaceutical Review

The Emergence of Biogenerics

Investors have big hopes for the generics industry. The market capitalisation of leading generics companies increased during the last decade, more so than that of major pharma companies, resulting in return-to-shareholders-to-earnings ratios close to the pharma average. This outperformance indicates the expectations for the future of the generics industry. Although many changes in industry structure are expected to trigger strong growth - such as internationalisation of European companies; consolidation; and innovation in pharmaceutical drug development - the most prominent challenge so far is the product pipeline.A look at published drug patent tables reveals a huge wave of patent expiry over the next four years, worth an estimated US$40 billion in product sales, and including as many as 18 blockbusters (1). For the first time, these tables also include pharmaceuticals that were biotechnologically developed and produced. These biopharmaceuticals are also expected to be launched by generics companies, as they account for about one-quarter of the US$40 billion total and represent one of the fastest growing segments in the pharmaceutical market (see Figure 1). In fact, 'biogenerics' will represent a US$2 billion market for the generics industry, assuming a similar penetration rate as that for traditional drugs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Klaus Maleck, Chief Financial Officer, and Federico Pollano, Head
of Business Development, at BioGeneriX AG

Dr Klaus Maleck studied biotechnology in Braunschweig, Strasbourg and Chapel Hill, and holds a PhD in Biochemistry from the Max-Planck-Institute in Cologne. After four years as a Genomics Scientist at Novartis Inc. in the US, he joined the McKinsey team in Munich to consult diverse life science companies on strategy and M&A activities. He is currently employed as Chief Financial Officer at BioGeneriX AG.
Federico Pollano started his career (after studying biology and computer science) in clinical research for the Zambon group in Munich. He then worked for Glaxo Wellcome in clinical research, pharmacoeconomics and disease management fields, before joining the business development unit in Germany, focusing on licensing and M&A. In 2001, he took over as Head of Business Development at BioGeneriX AG.

spacer
Klaus Maleck
spacer
spacer
spacer
Federico Pollano
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stevanato Group signs an agreement with Nelson Labs to provide best-in-class Extractables and Leachables testing services at its US Technology Excellence Center

Piombino Dese, Padua Italy and Salt Lake City, USA September 2, 2020: Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated services for combination products, and Nelson Laboratories, LLC, a global provider of lab testing and expert advisory services signed today a partnership agreement that will provide Extractables and Leachables testing at SG US Technology Excellence Center in Boston, MA.
More info >>

White Papers

PhlexEarchive: The Right Solution for Electronic Archiving of TMF Content

Phlexglobal Ltd

Many sponsor organizations have already recognized the value of moving from paper to electronic Trial Master Files (eTMFs). But few sponsors have taken a more holistic approach to the TMF lifecycle and looked at the entire process from study start-up through archiving of the TMF in electronic format, also known as e-archiving. The recurring value of managing, tracking, maintaining and accessing electronic files should not stop at the point of archiving. All of the challenges of managing an active paper TMF carry through to a paper archive. All of the benefits of an electronic TMF also carry through to the electronic archive. As companies look to move their compliance assets to secure, long-term storage, it is important to consider ongoing compliance requirements, security, accessibility, efficiency and costs of archiving TMF content in a digital format.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement